Safety and Effectiveness of Open-Label Clobazam in Subjects With Lennox-Gastaut Syndrome.

Trial Profile

Safety and Effectiveness of Open-Label Clobazam in Subjects With Lennox-Gastaut Syndrome.

Completed
Phase of Trial: Phase III

Latest Information Update: 28 Sep 2016

At a glance

  • Drugs Clobazam (Primary)
  • Indications Lennox-Gastaut syndrome
  • Focus Therapeutic Use
  • Sponsors Lundbeck Inc
  • Most Recent Events

    • 28 Sep 2016 Results of post-hoc analysis from OV-1004 and OV-1012 studies (n=200) published in the Neurology.
    • 28 Sep 2016 According to Lundbeck A/S media release, Barry Gidal, PharmD, University of Wisconsin School of Pharmacy & Dept. of Neurology is the lead investigator of the post-hoc analyses
    • 21 Apr 2016 Results of a post hoc analysis presented at the 68th Annual Meeting of the American Academy of Neurology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top